This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Vista Partners Initiates Coverage On ADVENTRX Pharmaceuticals, Inc.; Target Price $7.50

Stocks in this article: ANX

SAN FRANCISCO, June 22, 2011 /PRNewswire/ -- Vista Partners announced today that it has initiated coverage on ADVENTRX Pharmaceuticals, Inc. (AMEX: ANX) ("The Company" or "ANX"); with a twelve month target price of $7.50. Ross Silver, Principal Analyst at Vista Partners stated, “ANX has a diverse late stage clinical pipeline with two clinical candidates that could serve multi-billion dollar markets and one candidate with a Prescription Drug User Fee Act, or PDUFA, goal date of September 1, 2011 that could lead to approval by FDA as early as this year. ANX is developing a study protocol for ANX-514, a novel emulsion formulation of the chemotherapy drug docetaxel which serves a multi-billion dollar market. The Company is preparing ANX-514 for submission to the FDA and intends to continue discussions with the FDA regarding the planned Phase 3 clinical study and other requirements for approval of ANX-514. The company is developing its protocol for a pivotal Phase III trial scheduled to begin in 2012." Mr. Silver continues, "In April 2011, ANX completed the acquisition of SynthRx, Inc. SynthRx's lead product candidate is a novel, purified, rheologic and antithrombotic compound, purified poloxamer 188, which ANX is developing as ANX-188. Initially, ANX is developing ANX-188 as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis and, if ANX is able to reach agreement with FDA on a study protocol on a timely basis, ANX may initiate a Phase 3 clinical trial of ANX-188 for that indication in 2012." Mr. Silver concludes, "In November 2010, ANX submitted a new drug application, or NDA, for Exelbine™, or ANX-530, a novel emulsion formulation of the chemotherapy drug vinorelbine (Navelbine®), to the U.S. Food and Drug Administration, or FDA, and in January 2011, ANX announced that the FDA accepted the Exelbine™ NDA for filing and established a Prescription Drug User Fee Act, or PDUFA, goal date of September 1, 2011 to finish its review of the Exelbine™ NDA."

To download a FREE copy of the ADVENTRX Pharmaceuticals, Inc. research report, please visit http://www.vistapglobal.com and click the "download research" icon to gain access to the report.

About Vista Partners:

Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of profitable investment ideas.

Disclaimer & Disclosure:

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,659.10 -13.50 -0.08%
S&P 500 2,056.39 +4.57 0.22%
NASDAQ 4,770.7150 +12.8360 0.27%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs